ICER Releases Draft Evidence Report on Therapies for Lupus Nephritis

Also this morning, we published our Draft Evidence Report assessing the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals) and belimumab (Benlysta®, GlaxoSmithKline) for the treatment of lupus nephritis. We’re now accepting public comments through February 18.

NOTE: This preliminary draft marks the midpoint of ICER’s eight-month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions. Read more here.